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In this short work, by combining the total cell evolution curve and the two-compartment
model, the evolution of one of the subpopulations is simulated while the system interacts
with a proliferating regulatory factor.
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1. Introduction
In a model presented by Kozusko and Bajzer (KB model), a two-compartment cell population dynamics composed of
proliferating cells and quiescent cells was combined with the Gompertzian function. The dynamic of each compartment,
together with the evolution of the whole system in the form of Gompertzian growth, leads to the analytical solutions
expressing the evolution of each of the compartments [1]. In this context the Gompertzian function is expressed as:
N1(t) = N01 exp
[
k+
k−
(1− exp(−k−t))
]
(1)
where N1(0) = N01 and N1(t) stands for the total number of cells after time t during the growing phase. N01 represents
the initial cellularity. k+ represents a growth rate constant, while k− represents the retardation of growth. The two-
compartment model describes the evolution of the two compartments of a tumor. This model consists of proliferating, P1,
and quiescent, Q1, cell compartments. The index of 1 accounts for the tumor during the growing phase. The population of
the proliferating cells increases due to the reproduction rate, β , and both proliferating and quiescent cells decease by the
natural death rate of µp and µq. Also, in the model, the transition rate functions (ri(N1), ro(N1)) express the transition from
P cells to Q cells and vice versa, respectively, and are considered to be functions of the total number of cells. The evolution
of each of these two compartments can be expressed by the following ordinary differential equations [1]:
dP1
dt
= [β − µp − ro(N1)] P1 + ri(N1)Q1, (2a)
dQ1
dt
= ro(N1)P1 −
[
ri(N1)+ µq
]
Q1 (2b)
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where N1 = P1 + Q1 and P1(0) + Q1(0) = 1. As calculated in their paper, the analytical solution for the subpopulations is
expressed as below:
P1(t) = µq + k+ exp(−k−t)
β + µq + µp N1(t) = P0
µq + k+ exp(−k−t)
µq + k+ N1(t), (3)
The KB model is extended when the system interacts with anti-mitotic drugs [2]. In this model, the drug acts as an extra
killing factor for proliferating cells. It is also considered to be active and to decay as a function of time after being introduced
to the tumor. The analytical solution for the proliferating and quiescent cells is, then, obtained and the results are analyzed.
In the current short communication amore complete picture of the drug effect on the two-compartmentmodel is presented.
We have considered that the dynamic drug not only increases the death rate of the proliferating and quiescent cells, but can
also regulate the reproduction rate of the proliferating cells. In the following, the model and the analytical solutions are
presented and analyzed through a model simulation.
2. Extended KB Model interacting with dynamic proliferating regulating drugs
Many studies have investigated the effects of drugs on tumor growth fromdifferent perspectives [3–10]. In this study, the
drug is considered to increase the death rate of proliferating and quiescent subpopulations and to regulate the proliferating
reproduction rate in its dynamism a decay as a function of time. The response functions to drugs can be expressed as:
F(u) = ai(1− exp(−mu)), wherem is linked to pharmacokinetics and is considered to be 1 in this primary study [3]. In this
expression, 1− exp(−u) is the chemotherapy fractional cell control factor and u is the amount of the drug at a tumor site at
the specific time. The coefficient of ai is the response factor. The kinetics of the drug can be expressed as: du/dt = v(t)−d·u,
where v(t) is the given dose and d is the per capita decay rate. This work concentrates on the phase when the drug is no
longer being injected, v(t) = 0, and u has the exponentially decaying behavior of u(t) = u0 exp(−d · t) [3]. In this equation,
u(0) = u0 is the initial concentration of the drug. Tomodify the Kuzosko–Bajzermodel, these drug terms can be added to the
two-compartment model structure. The index of 2, in our notation, accounts for this interaction phase, where the total cell
population, N2, has a decaying behavior. The schematic view of the extended two-compartment model of cell populations
in the presence of chemotherapy is presented schematically in Fig. 1. As can be seen in Fig. 1, in the absence of any drugs,
u = 0, the system tends to the KB model [1], and when the proliferating reproduction rate does not respond to the drug,
aβ = 0, the system will tend toward the study done by Feizabadi et al. [2]. The modified differential equations presenting
the kinetics of the system are:
dP2
dt
= [β ′ − µp − ro(N2)− ap(1− exp(−u))] P2 + ri(N2)Q2, (4a)
dQ2
dt
= ro(N2)P2 −
[
ri(N2)+ µq + aq(1− exp(−u))
]
Q2, (4b)
N2 = P2 + Q2. (4c)
Note that in the above equations, the reproduction constant rate is regulated by the drug in the form of β ′ = β− aβ(1−
exp(−u)) Using Eqs. (4a) and (4b), we reform Eq. (4c) into:
dN2
dt
= [β ′ − µp + µq + (aq − ap)(1− exp(−u))] P2 − [µq + aq(1− exp(−u))]N2. (5)
which leads to:
P2(t) = dN2/dt +
[
µq + aq(1− exp(−u))
]
N2
β − µp + µq + (aq − ap − aβ)(1− exp(−u)) =
dN2/dt +
[
µq + aq(1− exp(−u))
]
N2
S + (aq − ap − aβ)(1− exp(−u)) (6)
where
S = −(aq − ap − aβ)(1− exp(−u0))+ N02P02
[
µq + aq(1− exp(−u0))
]+ dN02/dt
P02
The specification of Eq. (6) is at the boundary condition. At t = the starting point of the interacting phase, the size
of the proliferating cells is the same as the size of the proliferating cells at the end of the growing phase, phase 1. The
evolutionary behavior of the proliferating cells is simulated belowwhen the total cell population,N2 shows an exponentially
decaying behavior during the phase of interaction with the drug. The total cell population is considered to have a structure
of: N2 = N02 exp(−kt)when k is a decay constant and N02 = N1at-the-starting-of -therapy.
In this work, we assumed that the decay rate of the whole tumor during the course of therapy k is also dependent on the
drug’s effect and the initial decay rate k0 decreases upon the diffusion of the drug. So the proposed form isN2 = N0 exp(−kt)
when k = k0 exp(−akt). In this case ak is the response coefficient factor of the decay rate. The evolution of proliferating cells
is simulated in multi-steps. We first considered that the decay of the whole tumor k is constant and the drug increases the
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Fig. 1. Two-compartment model interacting with dynamic drugs.
C
B
D
A
Time
40.2 40.4 40.6 40.8 41.0 41.2 41.4
p0
p
7.5 ×107
7.×107
6.5 ×107
5.5 ×107
5.×107
4.5 ×107
4.×107
Fig. 2. The ratio of cell proliferating in the interaction phase vs. time. The common parameters are: K+ = 2.76, K− = 0.134, N01 = 1, µq = 0.2, ap = 0.9,
aq = 0.9, u0 = 1. The specific parameters are: A: k = 1, ak = 0, B: k = 1, ak = 0.05, C: k = 1, ak = 0.06, D: k = 1.1, ak = 0.06, aβ = 0.1.
death rate of P and Q cells Fig. 2(A). Then the decay of the cells of the whole tumor decreases by a different response factor
ak because of the diffusive nature of the drug. The smaller response factor, ak, leads to the smaller size of the P cells confirms
that the less drug diffusion is more effective in controlling the P-cells Fig. 2(B–C).
We then added the regulatory effect of the drug on the proliferating reproduction constant of β . In a successful therapy,
adding the β regulatory factor comes with the sharper decay constant during the phase of the therapy. To simulate the
behavior of the evolution of the P cells in this case, the response factor of aβ = 0.1 together with a sharper decay k0 = 1.1
is simulated in Fig. 2(D). As can be seen, the size of the proliferating rate was reduced by adding the β regulatory factor in a
successful therapy.
In this short communication, the ordinary differential equations for the kinetics of cancerous subpopulations aremodified
by adding terms which increase the death rate of the P-cells and Q -cells while decreases the proliferating reproduction
factor. Themodel shows that maximizing the parameters while observing the evolution of the whole cells of a tumor during
the course of therapy, can lead to a desirable outcome for the evolution of P-cells during the therapy.
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